A study testing whether a GLP-1 medicine, semaglutide, can help people with prediabetes lower blood sugar.
Recruiting now. Registry record last updated March 17, 2026.
- Who can join
- Adults 18+, have prediabetes, BMI 30+.
- What you take
- Semaglutide, given as part of the study. Check ClinicalTrials.gov for this trial's study groups, including any placebo or comparison medicine.
- How long it lasts
- The full study runs about 5 years.
- What you get
- Costs vary by study. Ask the study team what this one covers, including the study medicine, visits and travel, before you sign the consent form.
What this study is for
Primary condition: PreDiabetes.
Full scientific study title: Pharmacogenetics of the Response to GLP-1 in Mexican-Americans With Prediabetes.
Who can join
Adults 18+, have prediabetes, BMI 30+. A site coordinator confirms whether you qualify during a free screening visit. The exact medical requirements are below.
Full medical eligibility (for you and your doctor)verbatim from the registry
This is the exact wording from ClinicalTrials.gov, including clinical measures (lab values, imaging scores). Bring it to your doctor if any of it is unclear.
Key inclusion criteria
- Men and women, ages 18 years and older
- Diagnosis of Prediabetes - defined as either impaired fasting glucose (fasting glucose of 100-125 mg/dL), impaired glucose tolerance (2-hour postprandial blood glucose of 140-199 mg/dL after 75-gram oral glucose challenge), and/or a hemoglobin A1C ranging from 5.7% to 6.4%
- High risk for progression to diabetes: defined as having at least one of the two following additional factors: Obesity (BMI ≥ 30 kg/m2) and/or metabolically unhealthy status. "Metabolically unhealthy status" is defined as at least two of the following: elevated blood pressure (SBP ≥ 130 mmHg and/or DBP ≥ 85 mmHg), elevated triglycerides ≥ 150 mg/dL, low HDL cholesterol (males \< 40 mg/dL; females \< 50 mg/dL), and elevated fasting glucose ≥ 100 mg/dL (Wu S et al., 2017).
- Women of childbearing age must agree to use an acceptable method of pregnancy prevention (barrier methods, abstinence, hormonal contraception, intrauterine contraception, or surgical sterilization) for the duration of the study.
- Patients must have the following laboratory values: Hematocrit ≥ 34 vol%, estimated glomerular filtration rate ≥ 60 mL/min per 1.73 m2, AST (SGOT) \< 2.5 times ULN, ALT (SGPT) \< 2.5 times ULN, alkaline phosphatase \< 2.5 times ULN
Key exclusion criteria
- History of Type 1 or Type 2 diabetes mellitus
- Pregnant or breastfeeding women
- Medications: metformin, DPP-4 inhibitors, GLP-1 receptor agonists, SGLT-2 inhibitors, thiazolidinediones, insulin, sulfonylureas, meglitinides, alpha-glucosidase inhibitors, and/or corticosteroids over the last 3 months.
- Active malignancy
- History of clinically significant cardiac, hepatic, pancreatic or renal disease.
Where this trial is enrolling
This trial has 1 sites across 1 state. Contact a site coordinator directly to start screening.
Texas1 site
- UTHealth Clinical Research Unit (CRU) at UT BrownsvilleBrownsville, Texas
Timeline
Started enrolling: November 22, 2021. Expected completion: October 31, 2026. Last updated on ClinicalTrials.gov: March 17, 2026.
Official source
Every Monday we check this trial against ClinicalTrials.gov, the federal registry for clinical research. Last checked September 4, 2026. Confirm the current status there before you contact a site:
Other GLP-1 clinical trials
Back to the full directory → or take the matching quiz if you want clinical trials filtered to your conditions and location.
